Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma

Oncologist

Volumn 17, Issue 1, 2012, Pages 80-90

  Colpo, Anna ^a   Hochberg, Ephraim ^b   Chen, Yi Bin ^b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Autologous stem cell transplant; High dose chemotherapy; Hodgkin's lymphoma

Indexed keywords

BENDAMUSTINE; BIOLOGICAL MARKER; BRENTUXIMAB VEDOTIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; LENALIDOMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOGUAZONE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PREDNISOLONE; RAPAMYCIN; RITUXIMAB;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; HODGKIN DISEASE; HUMAN; INFECTION; LOW DRUG DOSE; LYMPH NODE IRRADIATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT FAILURE; WHOLE BODY RADIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84863070248     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0177     Document Type: Article

References (110)

1. Engert A, Plẗschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-652.
2. Eich HT, Diehl V, Görgen H et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final Analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010;28:4199-4206.
3. Bonadonna G, Viviani S, Bonfante V et al. Survival in Hodgkin's disease patients-report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 2005;41:998-1006.
4. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's Disease. N Engl J Med 2003;348:2386-2395.
5. Duggan DB, Petroni GR, Johnson JL et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an Intergroup trial. J Clin Oncol 2003;21:607-614.
6. Gallamini A, Patti C, Viviani S et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011;152:551-560.
7. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993;341:1051-1054.
8. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:Arandomised trial. Lancet 2002;359:2065-2071.
9. Puig N, Pintilie M, Seshadri T et al. Different response to salvage chemotherapy but similar posttransplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. Haematologica 2010;95:1496-1502.
10. Nademanee A, O'Donnell MR, Snyder D et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 1995;85:1381-1390.
11. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-623.
12. Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/-cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994;83:1193-1199.
13. Lavoie JC, Connors JM, Phillips GL et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: Long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106:1473-1478.
14. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506-1514.
15. Bierman PJ, Lynch JC, Bociek RG et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002;13:1370-1377.
16. Brice P, Bouabdallah R, Moreau P et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry. Société Frana̧ise de Greffe de Moëlle. Bone Marrow Transplant 1997;20:21-26.
17. Josting A, Franklin J, MayMet al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2002;20:221-230.
18. Sureda A, Constans M, Iriondo A et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16:625-633.
19. Moskowitz CH, Yahalom J, Zelenetz AD et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010;148:890-897.
20. Jabbour E, Hosing C, Ayers G et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007;109:2481-2489.
21. Becherer A, Mitterbauer M, Jaeger U et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002;16:260-267.
22. Spaepen K, Stroobants S, Dupont P et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003;102:53-59.
23. Svoboda J, Andreadis C, Elstrom R et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006;38:211-216.
24. Filmont JE, Gisselbrecht C, Cuenca X et al. The impact of pre-and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007;110:1361-1369.
25. Schot BW, Zijlstra JM, Sluiter WJ et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007;109:486-491.
26. Moskowitz AJ, Yahalom J, Kewalramani T et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010;116:4934-4937.
27. Banerjee D. Recent advances in the pathobiology of Hodgkin's lymphoma: Potential impact on diagnostic, predictive, and therapeutic strategies. Adv Hematol 2011;2011:439456. Epub 2011 Jan 18.
28. Steidl C, Lee T, Shah SP et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-885.
29. Smith SD, Moskowitz CH, Dean R et al. Autologous stem cell transplant for early relapsed/ refractory Hodgkin lymphoma: Results from two transplant centres. Br J Haematol 2011;153:358-363.
30. Martín A, Fernàndez-Jiménez MC, Caballero MD et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001;113:161-171.
31. Fernàndez-Jiménez MC, Canales MA, Ojeda E et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation. Haematologica 1999;84:1007-1011.
32. Aparicio J, Segura A, Garcerà S et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999;10:593-595.
33. Rodriguez J, Rodriguez MA, Fayad L et al. ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 1999;93: 3632-3636.
34. Josting A, Rudolph C, Mapara M et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005;16:116-123.
35. Hertzberg MS, Crombie C, Benson W et al. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol 2006;17(suppl 4):iv25-iv30.
36. Zinzani PL, Tani M, Molinari AL et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 2002;87:816-821.
37. Proctor SJ, Jackson GH, Lennard A et al. Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with highdose ifosfamide, etoposide and epirubicin: A Northern Region Lymphoma Group study (UK). Ann Oncol 2003;14(suppl 1):i47-i50.
38. Fermé C, Bastion Y, Lepage E et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995;6:543-549.
39. Fermé C, Mounier N, Diviné M et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'tudes des Lymphomes de l'Adulte H89 trial. J Clin Oncol 2002;20:467-475.
40. Baetz T, Belch A, Couban S et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003;14:1762-1767.
41. Chau I, Harries M, Cunningham D et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol 2003;120:970-977.
42. Bartlett NL, Niedzwiecki D, Johnson JL et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071-1079.
43. Suyani E, Sucak GT, Aki SZ et al. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol 2011;90:685-691.
44. Santoro A, Magagnoli M, Spina M et al. Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007;92: 35-41.
45. Kuruvilla J, Nagy T, Pintilie M et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006;106:353-360.
46. Abali H, Urn̈ Y, Oksz̈oǧlu B et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008;26:401-406.
47. Josting A, Rudolph C, Reiser M et al. Timeintensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002;13:1628-1635.
48. Sibon D, Ertault M, Al Nawakil C et al. Combined ifosfamide, etoposide and oxaliplatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: A prospective monocentre study on 34 patients. Br J Haemat 2011 Mar 8 [Epub ahead of print]. doi: 10.1111/j.1365-2141.2011.08594.x.
49. Moskowitz AJ, Hamlin PA Jr, Gerecitano J et al. Bendamustine is highly active in heavily pretreated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant. Blood 2009;114:720.
50. Shea TC, Beaven AW, Moore DT et al. Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: Increased toxicity without improvement in progression-free survival. Leuk Lymphoma 2009;50:741-748.
51. Tarella C, Cuttica A, VitoloUet al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003;97:2748-2759.
52. Josting A, Müller H, Borchmann P et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010;28: 5074-5080.
53. Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994;12:2527-2534.
54. Sureda A, Arranz R, Iriondo A et al. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autológo de Médula Osea Spanish Cooperative Group. J Clin Oncol 2001;19:1395-1404.
55. Yahalom J, Gulati SC, Toia M et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 1993; 11:1062-1070.
56. Perz JB, Giles C, Szydlo R et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: Treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant 2007;39:41-47.
57. Benekli M, Smiley SL, Younis T et al. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant 2008;41: 613-619.
58. Ulrickson M, Aldridge J, Kim HT et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: A single-institution experience. Biol Blood Marrow Transplant 2009;15:1447-1454.
59. Wadehra N, Farag S, Bolwell B et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006;12: 1343-1349.
60. Santos EC, Sessions J, Hutcherson D et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation-a similar experience. Biol Blood Marrow Transplant 2007;13:746-747.
61. Nieto Y, Anderlini P, Popat U et al. Gemcitabine, busulfan and melphalan (GemBuMel) is a new high-dose chemotherapy (HDC) regimen with high activity in refractory Hodgkin's lymphoma (HL) patients receiving an autologous stem-cell transplant (ASCT): A contemporaneous comparison with BEAM and busulfan/melphalan (BuMel). Blood 2010;116:690.
62. Visani G, Malerba L, Stefani PM et al. A novel high dose chemotherapy strategy with bendamustine in adjunct to etoposide, cytarabine and melphalan (BeEAM) followed by autologous stem cell rescue is safe and highly effective for the treatment of resistant/relapsed lymphoma patients: A phase I-II study on 44 patients. Blood 2010; 116(21):31.
63. Lane AA, McAfee SL, Kennedy J et al. Highdose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma. Leuk Lymphoma 2011; 52:1363-1366.
64. Josting A, Nogovà L, Franklin J et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005;23:1522-1529.
65. Goodman KA, Riedel E, Serrano V et al. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol 2008;26:5240-5247.
66. Lazarus HM, Crilley P, CiobanuNet al. Highdose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 1992;10: 1682-1689.
67. Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant. J Clin Oncol 1993;11: 704-711.
68. Wendland MM, Asch JD, Pulsipher MA et al. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol 2006;29:189-195.
69. Majhail NS, Bajorunaite R, Lazarus HM et al. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Br J Haematol 2009;147:129-139.
70. Moskowitz AJ, Perales MA, Kewalramani T et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009;146:158-163.
71. Horning S, Fanale M, deVos S et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort [abstract 18]. Ann Oncol 2008;19(suppl 4):iv120-iv1.
72. Regelink JC, van Roessel CHM, van Galen KPM et al. Long-term follow-up of tandem autologous stem-cell transplantation in multiple myeloma. J Clin Oncol 2010;28:e741-e743.
73. Lazarus HM, Stiff PJ, Carreras J et al. Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Biol Blood Marrow Transplant 2007;13:778-789.
74. Brice P, Divine M, Simon D et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/ GELA Study Group. Ann Oncol 1999;10:1485-1488.
75. Fung HC, Stiff P, Schriber J et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 2007; 13:594-600.
76. Morschhauser F, Brice P, Fermé C et al. Riskadapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/ refractory Hodgkin's lymphoma: Results of the prospective multicenter H96 trial by the GELA/ SFGM Study Group. J Clin Oncol 2008;26:5980-5987.
77. Corradini P, Sarina B, Farina L. Allogeneic transplantation for Hodgkin's lymphoma. Br J Haematol 2011;152:261-272.
78. Rapoport AP, Guo C, Badros A et al. Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004;34:883-890.
79. Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812-1821.
80. Chen R, Gopal AK, Smith SE et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010;116:283.
81. Schwering I, Bräuninger A, Klein U et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003;101:1505-1512.
82. Carlo-Stella C, Guidetti A, Viviani S et al. Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL). J Clin Oncol 2010;28(15 suppl): 3068.
83. Sureda A, Younes A, Ben-Yehuda D et al. Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant. Blood 2010;116:419.
84. Dutton A, Reynolds GM, Dawson CW et al. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005;205:498-506.
85. Johnston PB, Inwards DJ, Colgan JP et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320-324.
86. Younes A, Copeland A, Fanale MA et al. Phase I/II study of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma. Blood 2010;116:3964.
87. Böll B, Borchmann P, Topp MS et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 2010; 148:480-482.
88. Kuruvilla J, Taylor D, Wang L et al. Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. Blood 2008;112: 3052.
89. Fehniger TA, Larson S, Trinkaus K et al. A Phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2009;114:3693.
90. Younes A, Romaguera J, Hagemeister F et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98: 310-314.
91. Oki Y, Pro B, Fayad LE et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008;112:831-836.
92. Corazzelli G, Capobianco G, Arcamone M et al. Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX), a new effective cytoreductive/ mobilizing salvage regimen for relapsed and refractory Hodgkin lymphoma. Blood 2008;112: 2601.
93. Jones RJ, Gocke CD, Kasamon YL et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009;113:5920-5926.
94. Kasamon YL, Jones RJ, Levitsky HI et al. High-dose cyclophosphamide (Cy), rituximab, and a cancer vaccine for relapsed classical Hodgkin's lymphoma (cHL). Blood 2010;116:3954.
95. Fernàndez de Larrea C, Martínez C, Gaya A et al. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation. Ann Oncol 2010;21:1211-1216.
96. Rigacci L, Fabbri A, Puccini B et al. Oxaliplatin-based chemotherapy (dexamethasone, highdose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Cancer 2010;116:4573-4579.
97. Reece DE, Barnett MJ, Connors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991;9:1871-1879. Erratum in J Clin Oncol 1992;10:170.
98. Bierman PJ, Bagin RG, Jagannath S et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Longterm follow-up in 128 patients. Ann Oncol 1993;4: 767-773.
99. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993;81:1137-1145.
100. Bierman PJ, Anderson JR, Freeman MB et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 1996;7:151-156.
101. Caballero MD, Rubio V, Rifon J et al. BEAMchemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997;20:451-458.
102. Horning SJ, Chao NJ, Negrin RS et al. Highdose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997;89:801-813.
103. Sweetenham JW, Taghipour G, Milligan D et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997;20:745-752.
104. Wheeler C, Eickhoff C, Elias A et al. Highdose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997;3:98-106.
105. Arranz R, Tomàs JF, Gil-Fernàndez JJ et al. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): Comparative results with two CBV regimens and importance of disease status at transplant. Bone Marrow Transplant 1998;21:779-786.
106. Lazarus HM, Rowlings PA, Zhang MJ et al. Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999;17:534-545.
107. Lazarus HM, Loberiza FR Jr, Zhang MJ et al. Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the Autologous Blood and Marrow Transplant Registry (ABMTR). Bone Marrow Transplant 2001;27: 387-396.
108. Moskowitz CH, Kewalramani T, Nimer SD et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645-652.
109. Evens AM, Altman JK, Mittal BB et al. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Ann Oncol 2007;18:679-688.
110. Kebriaei P, Madden T, Kazerooni R et al. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biology Blood and Marrow Transplant 2011;17:412-420.